• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Olema Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    9/2/25 7:05:30 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OLMA alert in real time by email
    8-K
    0001750284false00017502842025-09-022025-09-02

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): September 02, 2025

     

     

    Olema Pharmaceuticals, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-39712

    30-0409740

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    780 Brannan Street

     

    San Francisco, California

     

    94103

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 415 651-3316

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    OLMA

     

    The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 7.01 Regulation FD Disclosure.

    On September 2, 2025, Olema Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it had entered into a new clinical trial collaboration and supply agreement (the “Agreement”) with Pfizer Inc. (“Pfizer”). A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 8.01 Other Events.

    As described above, on September 2, 2025, the Company announced that it had entered into the Agreement with Pfizer. Pursuant to the Agreement, the Company and Pfizer will evaluate in a Phase 1b/2 study the safety and combinability of palazestrant plus atirmociclib, Pfizer’s investigational, highly selective-CDK4 inhibitor, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (“ER+/HER2-”) metastatic breast cancer. Pfizer will supply atirmociclib for use in the Phase 1b/2 study and the Company will lead the conduct of the study. All clinical data and inventions relating to the combined use of atirmociclib and palazestrant resulting from the study will be jointly owned, with the Company maintaining full global commercial and marketing rights to palazestrant.

    This Agreement is the Company’s second clinical trial agreement with Pfizer. The companies’ previous agreement was established in November 2020 to evaluate palazestrant in combination with palbociclib (IBRANCE®) in patients with recurrent, locally advanced or metastatic ER+/HER2- breast cancer.

     

    Forward Looking Statements

    Statements contained in Item 8.01 of this Current Report on Form 8-K regarding matters that are not historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as “will” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include, but are not limited to, those related to Olema’s planned Phase 1b/2 study of the safety and combinability of palazestrant plus atirmociclib and those related to ownership of clinical data, commercial rights, marketing rights and inventions relating to the combined use of palazestrant and atirmociclib. Because such statements deal with future events and are based on Olema’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Olema could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, those discussed in the section titled “Risk Factors” in Olema’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and other filings and reports that Olema makes from time to time with the U.S. Securities and Exchange Commission. Except as required by law, Olema assumes no obligation to update these forward-looking statements, including in the event that actual results differ materially from those anticipated in the forward-looking statements.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit No.

     

    Description

    99.1

     

    Press Release, dated September 2, 2025, of Olema Pharmaceuticals, Inc.

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Olema Pharmaceuticals, Inc.

     

     

     

     

    Date:

    September 2, 2025

    By:

    /s/ Shane Kovacs

     

     

     

    Shane Kovacs
    Chief Operating and Financial Officer

     


    Get the next $OLMA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OLMA

    DatePrice TargetRatingAnalyst
    8/12/2025$20.00 → $21.00Buy
    Citigroup
    4/2/2024$24.00Buy
    Goldman
    1/30/2024$20.00Buy
    Citigroup
    7/21/2023$21.00Outperform
    Oppenheimer
    5/5/2023$16.00Overweight
    CapitalOne
    2/22/2023$12.00Outperform
    Credit Suisse
    7/6/2022$16.00Buy
    Canaccord Genuity
    6/9/2022$12.00Neutral → Buy
    H.C. Wainwright
    More analyst ratings

    $OLMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN FRANCISCO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 124,000 shares of the Company's common stock, effective as of September 2, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accord

    9/3/25 4:30:00 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer

    Study to explore the palazestrant-atirmociclib combination in approximately 35 patients with initiation anticipated in H2 2025 Results to inform potential pivotal Phase 3 trial of novel combination in frontline metastatic breast cancer setting SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced a new clinical trial collaboration and supply agreement with Pfizer Inc. (NYSE:PFE) in metastatic breast cancer. The companies will evaluate in a Phase 1b/2 s

    9/2/25 7:00:00 AM ET
    $OLMA
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Olema Oncology to Participate in Upcoming Investor Conferences

    SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: Citi's 2025 Biopharma Back to School ConferenceDate and Time: September 2, 2025 at 4 p.m. ETFormat: Fireside ChatLocation: Boston, MA Wells Fargo 2025 Healthcare ConferenceDate and Time: September 3, 2025 at 3:45 p.m. ETFormat: PresentationLocation: Boston, MA Cantor Global Healthcare Conference 2025Date and Time: Se

    8/20/25 4:30:00 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OLMA
    SEC Filings

    View All

    Olema Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)

    9/2/25 7:05:30 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Olema Pharmaceuticals Inc.

    10-Q - Olema Pharmaceuticals, Inc. (0001750284) (Filer)

    8/11/25 4:15:57 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Olema Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)

    8/11/25 4:08:25 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OLMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup reiterated coverage on Olema Pharmaceuticals with a new price target

    Citigroup reiterated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $21.00 from $20.00 previously

    8/12/25 8:24:27 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Olema Pharmaceuticals with a new price target

    Goldman initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $24.00

    4/2/24 7:41:58 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Olema Pharmaceuticals with a new price target

    Citigroup initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $20.00

    1/30/24 7:36:41 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OLMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Bain Capital Life Sciences Investors, Llc bought $1,727,370 worth of shares (300,000 units at $5.76) and disposed of 3,500,000 shares (SEC Form 4)

    4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

    1/13/25 4:34:40 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Graham G. Walmsley sold $4,730,137 worth of shares (700,761 units at $6.75) and bought $4,730,137 worth of shares (700,761 units at $6.75) (SEC Form 4)

    4/A - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

    12/18/24 6:52:04 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Graham G. Walmsley sold $4,730,137 worth of shares (700,761 units at $6.75) (SEC Form 4)

    4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

    12/17/24 7:52:19 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OLMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by See Explanation of Responses Bvf Partners L P/Il

    4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

    6/13/25 6:23:00 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Larson Yi

    4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

    6/13/25 5:00:33 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hrustanovic Gorjan

    4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

    6/13/25 5:00:23 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OLMA
    Leadership Updates

    Live Leadership Updates

    View All

    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 19,800 shares of the Company's common stock, effective as of March 3, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance w

    3/4/25 4:30:00 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary

    SAN FRANCISCO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Shawnte M. Mitchell, J.D., as Chief Legal Officer and Corporate Secretary. "We are pleased to welcome Shawnte to our executive team to lead our Legal function as we progress both our late-stage palazestrant programs and our OP-3136 KAT6 program through clinical development," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. "Her extensive e

    2/18/25 7:00:00 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

    ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

    11/24/24 7:27:00 PM ET
    $LIAN
    $MGTX
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $OLMA
    Financials

    Live finance-specific insights

    View All

    Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

    Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients with ER+/HER2- advanced or metastatic breast cancer With a median follow-up of 12 months, median progression-free survival (PFS) has not been reached6-month PFS rate was 73% in all patients, 81% in patients with ESR1 mutations, 70% in ESR1 wild-type patients, and 68% in patients with prior CDK4/6 inhibitor treatment; data continue to mature Conference call today at 8:00 a.m. ET SAN FRANCISCO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA),

    12/10/24 7:00:00 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

    SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that it will present new data from the Phase 1b/2 clinical study of palazestrant (OP-1250) in combination with CDK4/6 inhibitor ribociclib at the San Antonio Breast Cancer Symposium (SABCS 2024) being held December 10-13, 2024, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Poster Details Title: A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib, in patien

    11/25/24 5:30:00 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

    Across 50 treated patients, palazestrant (OP-1250) in combination with ribociclib was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of either therapy85% clinical benefit rate (CBR) observed to date across all CBR-eligible patients supports promising preliminary efficacy profile of the palazestrant-ribociclib combination Olema will host an investor conference call today at 8:00 a.m. ET SAN FRANCISCO, May 15, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted the

    5/15/24 7:01:00 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OLMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Olema Pharmaceuticals Inc.

    SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/11/24 4:30:15 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Olema Pharmaceuticals Inc.

    SC 13D/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/4/24 7:49:50 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Olema Pharmaceuticals Inc.

    SC 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    11/14/24 4:34:56 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care